At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 81 enrolled
Drug / intervention
Bomedemstatdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multi-Center, Open Label, Extension Study Evaluating the Safety and Efficacy of Bomedemstat for the Treatment of Patients With Myeloproliferative Neoplasms (MPNs) Enrolled in a Prior Bomedemstat Clinical Study
Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)·interventional·Posted Feb 4, 2022·Updated Sep 22, 2025
In Brief
A Phase 2 clinical trial evaluating Bomedemstat for Thrombocythemia, Essential and Primary Myelofibrosis. Completed, enrolled 81 participants across 19 sites in 7 countries.
Detailed Summary
This is a multi-center, open-label extension study to assess the long-term safety and efficacy of bomedemstat administered orally once daily in participants with a Myeloproliferative Neoplasm (MPN) who participated in a prior bomedemstat study such as, but not limited to, IMG-7289-CTP-102/MK-3543-002 (NCT03136185) and IMG-7289-CTP-201/MK-3543-003 (NCT04254978) (referred to hereafter as 'feeder studies').
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsThrombocythemia, Essential, Primary Myelofibrosis
CountriesAustralia, Germany, Hong Kong, Italy, New Zealand, United Kingdom, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20222023202420252026
Enrollment StartDec 2021
First PostedFeb 2022
Primary CompletionAug 2024
TodayJul 2026
First PostedFeb 4, 2022
Enrollment StartDec 15, 2021
Primary CompletionAug 22, 2024
TodayJul 2, 2026
Enrollment to primary: 2.7 yearsPosted 4.4 years ago
Interventions
Bomedemstatdrug
Capsule (oral)